Table 2.
CNS disease type and treatment/prophylaxis details
| Baseline parameter | All patients (n = 120) |
Prophylaxis: cohort A (n = 88) |
Treatment: cohort B (n = 7) |
Treatment: cohort C (n = 25) |
|---|---|---|---|---|
| Proportion treated for de novo disease [n (%)] | 107 (89.2) | 84 (95.5) | 6 (85.7) | 17 (68.0) |
| Proportion treated for relapsed disease [n (%)] | 13 (10.8) | 4 (4.5) | 1 (14.3) | 8 (32.0) |
| Mean time from diagnosis to first liposomal cytarabine injection (days) | 136 | 78.5 | 116 | 177 |
| Number of liposomal cytarabine injections [mean (range)] | 3.4 (1–8) | 3.1 (1–7) | 4.0 (1–7) | 4.3 (2–8) |
| Systemic low-dose chemotherapy [n (%)] | 94 (78.3) | 76 (86.3) | 7 (100.0) | 11 (44.0) |
| R-CHOP | 91 (75.8) | 73 (83.0) | 6 (85.7) | 9 (36.0) |
| R-CVP | 4 (3.3) | 2 (2.3) | 0 (0.0) | 2 (8.0) |
| Other chemotherapy | 3 (2.5) | 1 (1.1) | 1 (14.3) | 0 (0.0) |
| Systemic, CNS-penetrating chemotherapy [n (%)] | 25 (20.8) | 12 (13.6) | 0 (0.0) | 13 (52.0) |
| R-CODOXM/R-IVAC (in BL) | 3 (2.5) | 2 (2.3) | 0 (0.0) | 1 (4.0) |
| EVAP (in LBL) | 8 (6.7) | 8 (9.1) | 0 (0.0) | 0 (0.0) |
| R-CHOP/RHAD (in MCL) | 2 (1.7) | 2 (2.3) | 0 (0.0) | 0 (0.0) |
| MA/IVAC | 7 (5.8) | 0 (0.0) | 0 (0.0) | 7 (28.0) |
| ESHAP | 2 (1.7) | 0 (0.0) | 0 (0.0) | 2 (8.0) |
| RHAD | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (4.0) |
| R-CHOP/MTX | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (4.0) |
| IVAC | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (4.0) |
| Whole brain radiation therapy [n (%)] | 18 (15.0) | 0 (0.0) | 0 (0.0) | 18 (72.0) |
| Autologous stem cell transplant post-chemotherapy (consolidation or relapse) | 19 (15.8) | 16 (18.2) | 0 (0.0) | 3 (12.0) |
BL Burkitt’s lymphoma, CNS central nervous system, CT chemotherapy, ESHAP etoposide combined with solumedrol, high-dose cytarabine and platinum-based chemotherapy, EVAP etoposide combined with vinblastine, adriamycin and prednisolone in patients with LBL, IVAC ifosfamide, etoposide and high-dose cytarabine, LBL lymphoblastic lymphoma, MA/IVAC methotrexate and cytarabine administered in alternate cycles with IVAC, MCL mantle cell lymphoma, R-CHOP rituximab combined with cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin) and prednisone, R-CODOXM/R-IVAC rituximab plus cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate followed by rituximab in combination with IVAC in patients with BL, R-CVP rituximab plus cyclophosphamide, vincristine and prednisone, R-CHOP/RHAD R-CHOP followed by rituximab plus high-dose cytarabine according to the Nordic protocol in patients with MCL